Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFIK ABADIER

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1649253147
CMS profile
256213
Location
INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$153.51

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $153.51 10

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFIK ABADIER

NPI 1649253147 · CMS profile ID 256213

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649253147?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649253147?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649253147?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1649253147?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $153.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $14.4510/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949312645 CMS
Novartis Pharmaceuticals Corporation $14.5610/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893482129 CMS
PFIZER INC. $15.0709/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949333281 CMS
Esperion Therapeutics, Inc. $16.1909/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947239137 CMS
Novartis Pharmaceuticals Corporation $15.6608/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893482127 CMS
Novartis Pharmaceuticals Corporation $16.0408/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893482125 CMS
Novartis Pharmaceuticals Corporation $13.0406/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893482123 CMS
Janssen Pharmaceuticals, Inc $15.1605/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885938377 CMS
E.R. Squibb & Sons, L.L.C. $17.1503/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932873397 CMS
Boston Scientific Corporation $16.1902/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916583891 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,012.13 30
PY2020 $285.07 11
PY2021 $127.23 4
PY2022 $153.51 10
PY2023 $3,321.33 24
PY2024 $2,191.02 22
PY2025 $222.26 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $731.79 4
PY2025 Principal investigator $554,369.24 96
PY2024 Principal investigator $1,358,878.08 258
PY2023 Principal investigator $1,095,651.17 1,020
PY2022 Principal investigator $767,493.58 1,505
PY2021 Principal investigator $331,251.89 220
PY2020 Principal investigator $152,753.28 147
PY2019 Principal investigator $85,046.12 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

258 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170833
Principal investigator 1 Merck Sharp & Dohme LLC $10,919.73 12/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Noninterventional Study to Evaluate Inflammatory Biomarkers in Different Patient Populations Compared to Healthy Participants. No dispute reported 06/30/2026 1136398516
Principal investigator 1 ModernaTX, Inc. $13,998.13 12/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192362
Principal investigator 1 ModernaTX, Inc. $34,902.97 12/19/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192358
Principal investigator 1 ModernaTX, Inc. $33,221.52 12/06/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192270
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/06/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192272
Principal investigator 1 ModernaTX, Inc. $16,128.17 12/06/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192274
Principal investigator 1 ModernaTX, Inc. $2,600.00 12/02/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192276
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171019
Principal investigator 1 ModernaTX, Inc. $183,061.63 11/27/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192352
Principal investigator 1 ModernaTX, Inc. $10,000.00 11/11/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147192356
Principal investigator 1 Merck Sharp & Dohme LLC $15,000.00 11/05/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Noninterventional Study to Evaluate Inflammatory Biomarkers in Different Patient Populations Compared to Healthy Participants. No dispute reported 06/30/2026 1136398512
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 11/01/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155830
Principal investigator 1 Alnylam Pharmaceuticals Inc. $243.00 11/01/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155832
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121171037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,381.00 10/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155822
Principal investigator 1 ModernaTX, Inc. $7,250.00 10/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192340
Principal investigator 1 ModernaTX, Inc. $1,800.00 10/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192342
Principal investigator 1 ModernaTX, Inc. $102.45 10/15/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147192350
Principal investigator 1 Alnylam Pharmaceuticals Inc. $81.00 10/14/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155826
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 10/14/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155828
Principal investigator 1 ModernaTX, Inc. $2,500.00 10/14/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192348
Principal investigator 1 Alnylam Pharmaceuticals Inc. $81.00 10/09/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155824
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,381.00 10/02/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155820
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170741
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170755
Principal investigator 1 ModernaTX, Inc. $9,000.00 09/12/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192328
Principal investigator 1 ModernaTX, Inc. $399.12 09/12/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147192338
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,586.00 09/04/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155546
Principal investigator 1 ModernaTX, Inc. $2,719.49 09/04/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147192268
Principal investigator 1 ModernaTX, Inc. $12,529.35 09/02/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192334
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170793
Principal investigator 1 ModernaTX, Inc. $11,365.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192252
Principal investigator 1 ModernaTX, Inc. $1,575.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192254
Principal investigator 1 ModernaTX, Inc. $2,000.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192256
Principal investigator 1 ModernaTX, Inc. $1,659.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192258
Principal investigator 1 ModernaTX, Inc. $600.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192260
Principal investigator 1 ModernaTX, Inc. $2,250.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192262
Principal investigator 1 ModernaTX, Inc. $4,379.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192264
Principal investigator 1 ModernaTX, Inc. $650.00 08/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192266
Principal investigator 1 ModernaTX, Inc. $598.68 08/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192326
Principal investigator 1 ModernaTX, Inc. $7,517.61 08/01/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192322
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 07/18/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 07/18/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 07/18/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 07/18/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 07/18/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170809
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/17/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192246
Principal investigator 1 ModernaTX, Inc. $4,384.23 07/17/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192248
Principal investigator 1 ModernaTX, Inc. $10,000.00 07/17/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192250
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170699
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170733
Principal investigator 1 ModernaTX, Inc. $25,058.70 06/28/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192318
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.90 06/03/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155494
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,814.00 06/03/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155496
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,102.00 06/03/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155502
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,814.00 06/03/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155540
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,102.00 06/03/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155542
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170695
Principal investigator 1 ModernaTX, Inc. $100.50 05/31/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192314
Principal investigator 1 ModernaTX, Inc. $1,766.61 05/29/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192312
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,381.00 05/01/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155500
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170577
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170589
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170673
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170675
Principal investigator 1 ModernaTX, Inc. $5,550.00 04/19/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192308
Principal investigator 1 ModernaTX, Inc. $500.00 04/17/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192306
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,381.00 04/01/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121155498
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170533
Principal investigator 1 ModernaTX, Inc. $7,605.90 03/28/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192302
Principal investigator 1 ModernaTX, Inc. $105,212.41 03/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192290
Principal investigator 1 ModernaTX, Inc. $15,211.80 03/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192298
Principal investigator 1 ModernaTX, Inc. $6,695.00 03/20/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH, LLC - INVERNESS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147181313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $514.40 03/04/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155488
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,872.00 03/04/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155490
Principal investigator 1 Alnylam Pharmaceuticals Inc. $397.10 03/04/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121155492
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170565
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170571
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170575
Principal investigator 1 ModernaTX, Inc. $5,299.83 02/26/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192288
Principal investigator 1 ModernaTX, Inc. $88,151.74 02/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192238
Principal investigator 1 ModernaTX, Inc. $87,493.26 02/23/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147192240
Principal investigator 1 Novartis Pharmaceuticals Corporation $198,752.00 02/13/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH LLC
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1089695431
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $96,140.02 02/01/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
DDI Study CYP3A4/p-gp (perp) Inducer [patient study] - An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1123478603
Principal investigator 1 ModernaTX, Inc. $5,771.25 02/01/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147192242
Principal investigator 1 ModernaTX, Inc. $43,190.75 02/01/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults No dispute reported 06/30/2026 1147192244
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170483
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170503
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1121170507
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,839.50 01/30/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1089691845
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,447.70 01/30/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH LLC
A Randomized, Participant and Investigator Blinded, Sponsor Open-label, Placebo-controlled, Single Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) No dispute reported 06/30/2026 1089695539
Principal investigator 1 ModernaTX, Inc. $5,394.64 01/29/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192278
Principal investigator 1 ModernaTX, Inc. $33,948.18 01/16/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192282
Principal investigator 1 AstraZeneca Pharmaceuticals LP $175,714.81 01/10/2024 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi No dispute reported 06/30/2026 1110846995